<DOC>
	<DOCNO>NCT01054482</DOCNO>
	<brief_summary>This phase II trial compare neoadjuvant chemotherapy concurrent chemoradiotherapy patient locally advance non-small cell lung cancer ( NSCLC ) address optimal induction strategy .</brief_summary>
	<brief_title>Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy Locally Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Management locally advance non-small cell lung cancer ( NSCLC ) remain challenge . Both local relapse distant metastasis frequent , 5-year survival 3-17 % inoperable disease . Staging historically subdivide stage III disease clinical stage IIIA , think potentially amenable surgery , stage IIIB , treat defi nitive radiotherapy radiochemotherapy . This phase II trial compare neoadjuvant chemotherapy concurrent chemoradiotherapy patient locally advance NSCLC address optimal induction strategy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histopathologic diagnosis non smallcell lung cancer Clinical stage IIIA and/or IIIB without pleural effusion ECOG functional status 0 1 No renal function alteration ( GFR &gt; 50 % ) No hepatic function alteration ( ALT AST less 2 time normal value ) Leucocytes 2,000/mcl Hemoglobin 10mg/dL Platelets 100,000/mcl Active uncontrolled infection . Serious concomitant disorder would compromise safety patient compromise patient 's ability tolerate therapy . MI within precede 6 month symptomatic heart disease include unstable angina , congestive heart failure , uncontrolled arrhythmia . Significant neurological mental disorder . Second primary malignancy . Pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>neoadjuvant chemoradiotherapy</keyword>
</DOC>